There is a difference between reducing one brutal symptom and treating an entire condition. The new dronabinol trial in post-traumatic stress disorder makes that distinction worth protecting.
Published in Nature Medicine on 5 August, the German phase-two study found that a standardised oral form of THC reduced the frequency and intensity of PTSD-related nightmares more than placebo over ten weeks. It was multicentre, double-blind and randomised, with 171 adults assigned to either dronabinol or a matching placebo.
That is more rigorous evidence than the anecdotes and small studies that have shaped much of the debate around cannabis and trauma. It also comes with a significant caution: adverse events were more common with dronabinol, and seven serious adverse events occurred in the treatment group compared with none on placebo.
The honest reading is therefore neither “THC cures PTSD” nor “the result can be ignored”. A defined medicine produced a meaningful improvement in a defined symptom under clinical supervision. The benefit now needs to be weighed against the safety findings, tested over longer periods and separated from claims about cannabis products the trial never studied.
What the trial tested
Researchers recruited adults aged 18 to 65 with diagnosed PTSD and recurrent distressing nightmares at four specialist centres in Germany. Participants needed to experience at least two nightmares a week and meet a minimum threshold for nightmare frequency and intensity.
The paper reports that 171 people were randomised: 87 to dronabinol and 84 to placebo. Their average age was 37.9, and 79.3% were women.
Dronabinol is delta-9-tetrahydrocannabinol, or THC, supplied here as a controlled oral solution known as BX-1. It was not smoked or vaporised cannabis flower. Participants took one dose before bed, beginning at 2.5 mg and increasing gradually to an individually tolerated dose of up to 15 mg.
The first four weeks were used for titration. The following six weeks maintained the selected dose. Participants, treating staff, investigators and outcome assessors were masked to allocation.
The trial excluded people with a lifetime cannabis-use disorder, a recent substance- or alcohol-use disorder, acute suicidality or a psychotic disorder. Cannabis-based medicines, cannabis herb, sleep medicines and alpha-adrenergic drugs were not permitted during the study. Those conditions matter: they created a more controlled trial, but they also limit how readily the findings can be applied to the wider population seen in ordinary PTSD services.
What the main result means
The primary outcome used one item from the Clinician-Administered PTSD Scale for DSM-IV, known as CAPS-IV B2. It combines a clinician's assessment of nightmare frequency and intensity on a scale from zero to eight. Lower scores indicate fewer or less intense nightmares.
At week ten, the reduction was 1.50 points greater with dronabinol than with placebo. The 95% confidence interval ran from 0.71 to 2.28 points in favour of dronabinol, and the reported P value was below 0.001.
The standardised effect size, Cohen's d, was 0.65. In broad terms, that is a moderate effect rather than a marginal statistical difference.
This is the strongest part of the study. The outcome was specified in advance, assessed by clinicians and tested against placebo. A result of this size in a 171-person multicentre trial deserves serious attention.
It is still a narrow result. CAPS-IV B2 is one item measuring one symptom. Nightmares can be devastating—disrupting sleep, worsening daytime distress and making recovery harder—but improvement on this measure does not establish that dronabinol reduced the full burden of PTSD, restored functioning or improved long-term recovery.
The distinction matters because the public-facing version of a cannabis study often grows broader with every retelling. “A THC medicine reduced nightmare frequency and intensity” is supported by the trial. “Cannabis treats PTSD” is not.
The safety findings cannot be a footnote
Adverse events were reported by 78 of 87 people assigned to dronabinol, or 89.7%, compared with 64 of 84 people on placebo, or 77.1%.
The proportion stopping treatment because of an adverse event was not higher with dronabinol: five people in the treatment group, or 5.7%, compared with six people on placebo, or 7.2%.
The serious-event figures are more concerning. Seven participants receiving dronabinol—8% of that group—experienced a serious adverse event. None was reported in the placebo group.
The abstract does not describe the events, their timing or whether investigators judged them related to treatment. Without that detail, it would be wrong either to attribute every event to dronabinol or to wave the imbalance away. A clinically responsible interpretation has to hold both possibilities open until the complete safety data can be examined.
Ten weeks is also too short to resolve questions about tolerance, dependence, withdrawal, cognitive effects or whether nightmare benefit persists. The researchers themselves conclude that long-term efficacy and safety require further evaluation.
The study was investigator initiated and supported by an unrestricted grant from Bionorica, which also supplied the trial medicine. Industry support does not invalidate a result, but it increases the importance of transparent event reporting, accessible data and independent replication.
Dronabinol is not the same intervention as cannabis flower
The trial's active ingredient was THC, but formulation and delivery are part of the evidence.
Each participant received a measured oral solution, titrated in 2.5 mg steps, taken at a consistent time and monitored by a research team. The placebo was designed to match the treatment. Eligibility rules reduced some of the risks that would complicate unsupervised use.
That is not equivalent to choosing a strain, inhaling flower or taking an edible of uncertain composition. Oral THC is absorbed slowly and can produce delayed, prolonged and variable effects. Products differ in strength, minor cannabinoids and contaminants. A dose that is tolerable for one person may cause anxiety, dizziness, impairment or an unpleasant psychoactive response in another.
Nor does the trial support adding retail CBD. CBD was not the intervention. The medicine contained dronabinol alone.
This is more than a technical caveat. People living with PTSD may already use cannabis to cope with sleep disturbance, and a positive headline may feel like confirmation that any THC product will help. The trial offers evidence for a possible treatment pathway; it does not provide a safe self-treatment protocol.
How it fits with the wider evidence
Before this study, controlled cannabinoid evidence for PTSD nightmares was sparse. A small 2015 crossover trial of nabilone—a synthetic cannabinoid with THC-like activity—reported improvement in nightmares in ten Canadian military personnel. Earlier reports were largely open-label, retrospective or observational.
A 2021 placebo-controlled crossover study of three smoked cannabis preparations did not find a significant difference between active cannabis and placebo in overall PTSD symptom change during its first treatment stage. Its sample was small and each treatment period lasted only three weeks, but the result is an important warning against treating all cannabinoid studies as interchangeable.
A major 2026 systematic review and meta-analysis in The Lancet Psychiatry found no convincing evidence that cannabinoids were effective for PTSD or other mental disorders across the evidence then available. The new dronabinol paper was published after that review's search window and answers a narrower question with a stronger design.
The studies are not necessarily contradictory. A medicine might help a particular symptom without treating the whole disorder. That is exactly why endpoints, formulation and population matter.
What this means for patients in the UK
The result does not change UK treatment guidance or create a new approved indication.
NICE recommends trauma-focused psychological treatment for adults with PTSD, including trauma-focused cognitive behavioural therapy and eye movement desensitisation and reprocessing. Targeted CBT for symptoms such as sleep disturbance can be considered when a person cannot or does not want to engage in trauma-focused work, or when symptoms remain afterwards.
Dronabinol is not recommended by NICE for PTSD-related nightmares. The NHS says cannabis-based medicine is prescribed only in limited circumstances, and THC-containing products can carry risks including psychosis and dependence as well as dizziness, tiredness, mood change and interactions with other medicines.
Someone already receiving prescribed medical cannabis should not change their dose or timing on the basis of this article. Someone experiencing trauma-related nightmares should speak to a GP or mental-health professional rather than trying to reproduce the trial. Severe worsening, suicidal thoughts or an immediate risk of harm require urgent support.
The practical relevance for the UK is research, not immediate access. The study gives funders and clinicians a credible reason to test a standardised cannabinoid medicine for a specific, disabling symptom. A UK trial would need to examine how it sits alongside trauma-focused care, which patients are most likely to benefit and whether the serious-event imbalance is repeated.
What should happen next
First, the full adverse-event table needs close scrutiny. Readers need to know the nature, severity, timing and assessed relationship of the seven serious events, as well as any changes in anxiety, dissociation, suicidality and daytime impairment.
Second, the result should be replicated independently. A confirmatory trial should be large enough to assess uncommon harms and should include longer follow-up after treatment stops.
Third, research should measure outcomes beyond nightmare scores: sleep quality, daytime functioning, PTSD severity, quality of life, therapy engagement and return of nightmares after withdrawal. Active-blinding questions also matter because psychoactive effects can allow participants to guess which group they are in.
Finally, future studies should test where a nightmare-focused medicine belongs in care. Is it a short-term bridge that makes psychological treatment more tolerable? An option for persistent nightmares after therapy? Or a treatment whose risks outweigh its benefit for some groups? Placebo alone cannot answer those service-level questions.
The editorial view
This is an important study because it moves the discussion away from testimonials and towards a testable medical claim.
The trial did not ask whether cannabis is good or bad for PTSD. It asked whether a carefully dosed oral THC medicine could reduce recurrent nightmares in a selected group of adults. On its primary measure, the answer was yes.
That answer should survive intact—without being inflated into a cure and without being dismissed because the active ingredient is politically contentious.
The seven serious adverse events in the dronabinol group also have to survive intact. They are not a reason to erase the efficacy result, but they are a reason to resist casual prescribing claims and demand better long-term evidence.
Progress in cannabinoid medicine depends on this kind of precision. A promising result can be real, clinically meaningful and still incomplete. Patients deserve the hope contained in the evidence, not the certainty added by a headline.
Key takeaways
- A multicentre, double-blind phase-two trial randomised 171 adults with PTSD-related nightmares to oral dronabinol or placebo for ten weeks.
- Dronabinol produced a 1.50-point greater reduction on a clinician-rated nightmare frequency and intensity measure, with a moderate standardised effect size of 0.65.
- The trial tested a measured oral THC medicine titrated from 2.5 mg to a maximum of 15 mg—not cannabis flower, retail CBD or unsupervised edibles.
- Adverse events were more common with dronabinol, while treatment discontinuation due to adverse events was similar between groups.
- Seven serious adverse events occurred with dronabinol and none with placebo; the published abstract does not provide enough detail to determine causality.
- The result supports further research into a specific PTSD symptom. It does not show that cannabis treats PTSD as a whole or justify self-medication.
- UK guidance continues to prioritise trauma-focused CBT and EMDR; this study does not change prescribing recommendations.
Sources
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial — Nature Medicine
- THC-PTSD trial registration NCT04448808 — ClinicalTrials.gov
- THC-PTSD trial protocol — BMC Psychiatry
- Post-traumatic stress disorder: recommendations — NICE guideline NG116
- Medical cannabis and cannabis oils — NHS
- Cannabinoids for mental and substance-use disorders: systematic review and meta-analysis — The Lancet Psychiatry
- Smoked cannabis preparations versus placebo for PTSD symptoms — PLOS ONE
